Clinical trials involving the editing of genes in sperm, eggs and early-stage embryos could be permitted under certain conditions, the National Academies of Sciences and the National Academy of Medicine recommended Tuesday in a long-awaited report. Once technical questions are resolved, clinical
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp